Celerion Expands NASH Biomarkers Services With the Implementation of FibroScan
Celerion, a leader in early clinical research, is pleased to announce the implementation of FibroScan®...
AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
AbbVie ,a research-based global biopharmaceutical company, announced that it will assume full development and commercial...
Arzeda Leverages Scalable Synthetic Biology Resources to Drive Computational Protein Design Platform
Arzeda, the Protein Design Compan, Twist Bioscience Corporation, TeselaGen Biotechnology Inc. and Labcyte Inc. have...
DSCSA one-month countdown
From 27 November 2018, the Drug Supply Chain Security Act (DSCSA) will be actively enforced...
Collaboration to identify biomarkers that predict therapeutic response
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG announced a collaboration to...
Is the market now DSCSA ready?
Roundtable questionsIn November 2017, the pharma industry was granted an extension of the Drug Supply...
Oxford Genetics extends its CRISPR Gene Editing Technology License Agreement from ERS Genomics to...
Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery,...
Quicker, More Accurate Diagnoses for Dangerous Diseases and Genetic Disorders
Standfirst:There is growing awareness of the valuable role that diagnostics can play, both in the...
Looking Towards the Future: Worldwide Biosimilar Uptake and Pricing
What is a biosimilar?
Whereas generic drugs are identical copycats of small-molecule chemical products, biosimilars are...
Risking Addiction for Relief: Is There a Better Alternative to Opioids?
Every day, the United States loses 116 lives to the opioid epidemic.(1) Pharmacists are asking...
